TFF Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary

• TFF Pharmaceuticals Inc TFFP.OQ reported a quarterly adjusted loss of 81 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-2.25. The lone analyst forecast for the quarter was for a loss of 81 cents per share.

• Revenue fell 17.7% to $193.39 thousand from a year ago; analysts expected $200.00 thousand.

• TFF Pharmaceuticals Inc's reported EPS for the quarter was a loss of 81 cents​.

• The company reported a quarterly loss of $3.54 million.

• TFF Pharmaceuticals Inc shares had fallen by 82.6% this quarter and lost 95.0% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for TFF Pharmaceuticals Inc is $30.00

This summary was machine generated from LSEG data November 22 at 10:00 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)